A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 251 participants.
Also called NCT06441630
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 251 participants
- Sponsor
- Registry
-
NCT06441630
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06441630. Randomized; double masking; primary purpose treatment. Start 2024-07-31 (actual); primary completion 2025-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
- Condition
- Essential Hypertension
- Intervention (Drug)
- AD-227A
- Intervention (Drug)
- AD-227B
- Intervention (Drug)
- AD-227C
- Intervention (Drug)
- Placebo of AD-227B
- Intervention (Drug)
- Placebo of AD-227C
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct06441630- Content hash
5cf7852b32d5c55e586561b110f0d3fd962cdf7d744aca9efdc1706ec261a2b2